Streetbeat News

Analyst Ratings

IDYA

IDEAYA Biosciences shares are trading higher after SVB Leerink initiated coverage on the stock with an Outperform rating and a $33 price target.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2023 | 5:02 pm

GFS

Analysts have provided bullish and somewhat bullish ratings for GLOBALFOUNDRIES (NASDAQ:GFS) in the last quarter. The average 12-month price target for the company is $74.0, a decrease of 4.82% from the previous average price target of $77.75.

Portfolio Pulse from Benzinga Insights

August 09, 2023 | 5:02 pm

DUK

Analysts have provided various ratings for Duke Energy (DUK) in the last quarter, with 2 bullish, 4 somewhat bullish, and 6 indifferent. The company has an average 12-month price target of $103.0, a decrease of 3.83% from the previous average price target of $107.10.

Portfolio Pulse from Benzinga Insights

August 09, 2023 | 5:02 pm

TTGT

Four analysts have provided ratings for TechTarget (NASDAQ:TTGT) in the last quarter, with an average price target of $34.25, compared to its current price of $31.74. This represents a decrease of 18.45% from the previous average price target of $42.00.

Portfolio Pulse from Benzinga Insights

August 09, 2023 | 5:02 pm

ENR

In the last quarter, Energizer Hldgs (NYSE:ENR) received 2 somewhat bullish and 2 indifferent ratings from analysts. The company's average 12-month price target is $37.0, representing a 4.52% decrease from the previous average price target of $38.75.

Portfolio Pulse from Benzinga Insights

August 09, 2023 | 5:02 pm

BL

JMP Securities analyst Patrick Walravens maintains a Market Outperform rating on BlackLine (NASDAQ:BL) but lowers the price target from $87 to $81.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 5:01 pm

KPRX

Maxim Group analyst Michael Okunewitch maintains a 'Buy' rating on Kiora Pharmaceuticals (NASDAQ:KPRX), but has lowered the price target from $12 to $2.

Portfolio Pulse from jenniferd'souza@benzinga.com

August 09, 2023 | 5:01 pm

BEAM

Credit Suisse has maintained its Neutral rating for Beam Therapeutics (NASDAQ:BEAM) and increased its price target from $46.00 to $47.00. Beam Therapeutics' shares are currently trading down 0.76% at $26.05 per share. A move to $47.00 would represent an 80.42% increase from the current share price.

Portfolio Pulse from Benzinga Insights

August 09, 2023 | 5:01 pm

SQSP

Goldman Sachs has maintained its Neutral rating for Squarespace (NYSE:SQSP) and raised its price target from $30.00 to $34.00. This would account for a 10.25% increase from the current share price. Squarespace's shares are currently trading up 0.39% over the last 24 hours.

Portfolio Pulse from Benzinga Insights

August 09, 2023 | 5:01 pm

UTI

Rosenblatt has maintained its Buy rating for Universal Technical (NYSE:UTI) and increased its price target from $9.00 to $11.00. Universal Technical's shares are currently trading at $8.02, and a move to $11.00 would represent a 37.16% increase.

Portfolio Pulse from Benzinga Insights

August 09, 2023 | 5:01 pm